General Information of Drug (ID: DM7L91K)

Drug Name
BAY1179470 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM7L91K

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pemigatinib DM819JF Cholangiocarcinoma 2C12.10 Approved [3]
Interferon Alfa-2a, Recombinant DMUTZ8S Chronic HCV-1 infection 1E51.1 Approved [4]
Palifermin DM9JOYP Oral mucositis DA01.11 Approved [5]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [6]
Trafermin DMLKI2B Periodontitis DA0C Phase 3 [7]
Debio 1347 DMZW50O Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
LY2874455 DMZ0DMY Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [10]
AEE-788 DMEOS5K Solid tumour/cancer 2A00-2F9Z Phase 1/2 [11]
Alofanib DMIEKTF Gastric adenocarcinoma 2B72 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor receptor 2 (FGFR2) TTGJVQM FGFR2_HUMAN Antagonist [2]

References

1 ClinicalTrials.gov (NCT01881217) First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors. U.S. National Institutes of Health.
2 National Cancer Institute Drug Dictionary (drug id 751593).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
5 Keratinocyte growth factor. Expert Opin Biol Ther. 2009 Jun;9(6):779-87.
6 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
7 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Company report (Eli Lilly) (drug: LY2874455)
10 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
11 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
12 Corrigendum to 'Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models' [Eur J Cancer 61 (2016) 20-28]. Eur J Cancer. 2017 Jan;70:156.